





Ms. KIM CANDICE GOTORA

PID NO:

Age: 37 Years Sex: Female



Reference: Dr. FARHAN

Sample Collected At:

CITICARE MEDICAL CENTER

Unit G03, Al Barsha South Bldg, Al Barhsa South

Third, Dubai

VID: 5050104647

Registered on:

Reported on:

12-May-2025 05:21 PM

Collected on:

11-May-2025 09:15 PM

12-May-2025 06:34 PM

Observed Value Biological Reference Interval Investigation Flag <u>Unit</u>

FOLLICLE STIMULATING HORMONE (FSH)

(Serum, ECLIA)

5.15

mIU/mL

Follicular phase: 2.5 - 10.2 Midcycle Peak: 3.4 - 33.4 Luteal Phase: 1.5 - 9.1 Postmenopausal: 23 - 116.3

Pregnant: < 0.3

INTERPRETATION:

- Increased level of FSH and LH are found in hypogonadism, anorchia, gonadal failure, complete testicular feminization syndrome, menopause, Klinefelter syndrome, alcoholism, and castration.
- Decreased level is seen in pituitary or hypothalamic failure

DR. ADLEY MARK FERNANDES M.D (Pathology) Pathologist

DR. VYOMA SHAH M.D (Pathology) **Clinical Pathologist**

Page 1 of 3

M RASHID CHENANGADATH

Laboratory Technologist

This is an Electronically Authenticated Report.

Test result pertains only to the sample tested and to be interpreted in the light of clinical history. These tests are accredited under ISO 15189 unless specified by (*).











Ms. KIM CANDICE GOTORA

PID NO:

Age: 37 Years Sex: Female

Sample Collected At:

CITICARE MEDICAL CENTER

Reference: Dr. FARHAN

Unit G03, Al Barsha South Bldg, Al Barhsa South

Third, Dubai

VID: 5050104647

Registered on:

12-May-2025 05:21 PM

Collected on:

11-May-2025 09:15 PM

Reported on:

12-May-2025 06:34 PM

LUTEINISING HORMONE (LH)

(Serum, ECLIA)

5.96

IU/L

Follicular Phase: 1.9 - 12.5

Mid Cycle Peak: 8.7 - 76.3 Luteal phase : 0.5 - 16.9 Post Menopausal: 15.9 - 54.0

Pregnant: < 0.1 - 1.5 Contraceptives: 0.7 - 5.6

INTERPRETATION:

- LH is a glycoprotein hormone co-secreted with FSH by Anterior pituitary gland which together control growth and reproductive activities of the gonadal tissues.
- LH is increased in Luteal Phase of Menstrual cycle, Complete testicular feminization syndrome, Primary hypogonadism(anorchia, testicular failure, menopause), Precocious puberty (either idiopathic or secondary to a central nervous system lesion)
- LH is decreased in: Primary ovarian hyperfunction in females, Primary hypergonadism in male, In failure of the pituitary orhypothalamus, Hyperprolactinemia, Polycystic Ovary disease (PCOS).

Clinical Utility:

- An adjunct in the evaluation of menstrual irregularities
- **Evaluating infertility**
- Predicting ovulation in IVF Treatment
- Diagnosing pituitary disorders

Caution:

Patients on Biotin supplement may have interference in some immunoassays. With individuals taking high dose Biotin(more than 5 mg per day) supplements, at least 8-hour wait time before blood draw is recommended.

Disclaimer Because of episodic, circadian and cyclic nature of LH secretion, clinical evaluations may require determinations in pooled multiple serial samples.

FSH-LH Testosterone, AMH- Mullerian inhibiting substance, Inhibin B, PCOS Profile.

References:

- Package insert
- Wallach's interpretation of diagnostic tests, Ed10, 2015
- Arch Pathol Lab Med—Vol 141, November 2017
- Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Burtis CA, Ashwood ER, Bruns DE, eds. 5th edition, St. Louis: Elsevier Saunders; 2014.

DR. ADLEY MARK FERNANDES M.D (Pathology) **Pathologist**

DR. VYOMA SHAH M.D (Pathology) **Clinical Pathologist**

Page 2 of 3

M RASHID CHENANGADATH

Laboratory Technologist

This is an Electronically Authenticated Report.

Test result pertains only to the sample tested and to be interpreted in the light of clinical history. These tests are accredited under ISO 15189 unless specified by (*).











Ms. KIM CANDICE GOTORA

PID NO:

Age: 37 Years Sex: Female



Reference : Dr. FARHAN
Sample Collected At :

CITICARE MEDICAL CENTER

Unit G03, Al Barsha South Bldg, Al Barhsa South

Third, Dubai

VID: 5050104647

Registered on : 12-May-2025 05:21 PM

Collected on :

11-May-2025 09:15 PM

Reported on :

12-May-2025 06:34 PM

<u>Investigation</u> <u>Observed Value</u> <u>Unit</u> <u>Biological Reference Interval</u> <u>Flag</u>

PROLACTIN 348.00 mIU/L Refer to Interpretation.

INTERPRETATION:

(Serum, ECLIA)

FEMALE REFERENCE RANGE (Please note change):

Stages	Reference Range (mIU/L)	
Tanner Stage I:	76.596 - 255.319	Source: Quest Diagnostics
Tanner Stage II-III:	55.319 - 382.979	Source: Quest Diagnostics
Tanner Stage IV-V:	68.085 - 425.532	Source: Quest Diagnostics
Non Pregnant:	102-496	Source: Roche Cobas Elecsys IFU
Pregnant:	212.766 - 4446.808	Source: Quest Diagnostics
Postmenopausal:	42.553 - 425.532	Source: Quest Diagnostics

^{*} High prolactin level is seen in pituitary gland tumour(prolactinoma), diseases of the hypothalamus, pregnancy, PCOS, liver disease (cirrhosis), kidney disease, anorexia nervosa hypothyroidism. Drugs that can cause an elevated prolactin include estrogen, tricyclic antidepressants, risperidone, opiates, amphetamines.

----- End Of Report -----

ayana V. Shah

DR. VYOMA SHAH

M RASHID CHENANGADATH

M.D (Pathology)
Pathologist

M.D (Pathology) Clinical Pathologist Laboratory Technologist

This is an Electronically Authenticated Report.

DR. ADLEY MARK FERNANDES







Printed on: 12-May-2025 06:35 PM

Test result pertains only to the sample tested and to be interpreted in the light of clinical history. These tests are accredited under ISO 15189 unless specified by (*).

^{*} Levels of prolactin that are below normal are not usually treated but may be indicative of a general decrease in pituitary hormones caused by a pituitary disorder such as hypopituitarism. drugs such as dopamine, levodopa and ergot alkaloid derivatives decrease prolactin level.